CN113166105A - 作为cdk-hdac双通路抑制剂的杂环化合物 - Google Patents

作为cdk-hdac双通路抑制剂的杂环化合物 Download PDF

Info

Publication number
CN113166105A
CN113166105A CN201980079367.8A CN201980079367A CN113166105A CN 113166105 A CN113166105 A CN 113166105A CN 201980079367 A CN201980079367 A CN 201980079367A CN 113166105 A CN113166105 A CN 113166105A
Authority
CN
China
Prior art keywords
compound
reaction
group
independently
optionally containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079367.8A
Other languages
English (en)
Inventor
张汉承
叶向阳
程鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Innogate Pharma Co Ltd
Original Assignee
Hangzhou Innogate Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Innogate Pharma Co Ltd filed Critical Hangzhou Innogate Pharma Co Ltd
Publication of CN113166105A publication Critical patent/CN113166105A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供如下所示的式(1)的化合物，包括它们的可能的对映异构体和非对映异构体，及其药学上可接受的盐，水合物或溶剂合物。本发明还提供了这些化合物的药物组合物，其制备方法，以及它们在治疗疾病和病症(包括癌症)中的用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980079367.8A 2018-11-30 2019-12-02 作为cdk-hdac双通路抑制剂的杂环化合物 Pending CN113166105A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018114573098 2018-11-30
CN201811457309 2018-11-30
PCT/CN2019/122503 WO2020108661A1 (zh) 2018-11-30 2019-12-02 作为cdk-hdac双通路抑制剂的杂环化合物

Publications (1)

Publication Number Publication Date
CN113166105A true CN113166105A (zh) 2021-07-23

Family

ID=70852662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079367.8A Pending CN113166105A (zh) 2018-11-30 2019-12-02 作为cdk-hdac双通路抑制剂的杂环化合物

Country Status (3)

Country Link
US (1) US20220041577A1 (zh)
CN (1) CN113166105A (zh)
WO (1) WO2020108661A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN113880809B (zh) * 2020-07-03 2022-10-18 盛世泰科生物医药技术(苏州)有限公司 一种嘧啶类衍生物及其制备方法和应用
CN113248500B (zh) * 2021-06-10 2021-10-19 中国药科大学 氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725A (zh) * 2008-12-22 2011-11-30 伊莱利利公司 蛋白激酶抑制剂
CN105294655A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
CN107793399A (zh) * 2016-09-07 2018-03-13 上海翰森生物医药科技有限公司 Cdk4/6抑制剂及其制备方法和应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725A (zh) * 2008-12-22 2011-11-30 伊莱利利公司 蛋白激酶抑制剂
CN105294655A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
CN107793399A (zh) * 2016-09-07 2018-03-13 上海翰森生物医药科技有限公司 Cdk4/6抑制剂及其制备方法和应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂

Also Published As

Publication number Publication date
WO2020108661A1 (zh) 2020-06-04
US20220041577A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CN113166105A (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN113544128A (zh) Kras-g12c抑制剂
CN113286794A (zh) Kras突变蛋白抑制剂
US20230174526A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
TW202043212A (zh) Shp2抑制劑及其應用
CN102014914A (zh) 3h-[1,2,3]***并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
CN112552295A (zh) Kras突变蛋白抑制剂
CN103261167A (zh) 取代的6，6-稠合含氮杂环化合物及其用途
CN116113632A (zh) 杂环类衍生物、其制备方法及其医药上的用途
JP6380777B2 (ja) ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
CN110997669A (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
KR20170003688A (ko) 단백질 탈아세틸화효소 억제제 및 이중 단백질 탈아세틸화효소-단백질 키나제 억제제로서의 헤테로사이클릭 하이드록삼산 및 그 이용 방법
CN112409376A (zh) 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
CN115160309B (zh) Krasg12c突变蛋白杂环类抑制剂的制备及其应用
CN110770234A (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
CN112513041B (zh) 三环化合物
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
CN113166148B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
CA3130471C (en) Pan-raf kinase inhibitor and use thereof
WO2021008338A1 (zh) 极光激酶抑制剂及其用途
CN110357905B (zh) 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN115466289A (zh) 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination